Mydecine Innovations Group Inc.

Mydecine Innovations Group Inc. is a biotechnology and life sciences company focused on the research, development, and commercialization of psychedelic-assisted therapeutics targeted at mental health conditions. The company develops nature-sourced compounds, including purified psilocybin-based drug candidates such as MYCO-001, aimed at treating disorders like nicotine addiction and post-traumatic stress disorder (PTSD). It also works on novel molecules with enhanced safety and efficacy profiles, advancing these through pre-clinical stages toward human clinical trials. In addition to drug development, the company operates a digital telehealth platform named Mindleap, which facilitates access to mental health and psychedelic integration services. Mydecine Innovations Group maintains a comprehensive intellectual property portfolio across molecules, formulations, delivery methods, and production processes. Collaborations with research institutions globally support its clinical initiatives, highlighting its role in pioneering innovative mental health treatments and enhancing wellbeing through nature-sourced psychedelic therapies.